Skip to main content

Table 1 Characteristics of the 14 including articles

From: Effects of bisphosphonates in preventing periprosthetic bone loss following total hip arthroplasty: a systematic review and meta-analysis

Study (author/year) Country Primary disease Type of THA Type of BPs Control group Men Women Treatment duration Time of following Loss to follow-up
BPs control BPs control BPs control BPs control BPs control
Tapaninen TS/2010 [18] Finland Primary hip osteoarthritis Uncemented Alendronate (G3) Calcium 2 5 5 4 0.5 year 0.5 year 5 years 5 years 0 0
Trevisan C/2010 [19] Italy NA Uncemented Clodronate (G2) No medication 26 27 16 22 1 year No medication 1 year 1 year 4 8
Arabmotlagh M/2009 [20] Germany Degenerative osteoarthritis Uncemented Alendronate (G3) No medication 16 9 13 11 5/10 weeks No medication 6 years 6 years 2 1
Yamasaki S/2007 [21] Japan Osteoarthritis secondary to acetabular dysplasia Uncemented Risedronate (G3) Placebo 2 2 17 19 0.5 year 0.5 year 0.5 year 0.5 year 3 0
Fokter SK/2006 [22] Slovenia Primary or secondary osteoarthritis Cemented Etidronate (G1) Placebo 6 3 12 10 1 year 1 year 1 year 1 year 2 1
Arabmotlagh M/2006 [23] Germany Degenerative primary osteoarthritis Uncemented Alendronate (G3) Placebo 14 12 13 12 0.5 year 0.5 year 52 weeks 52 weeks 0 0
Yamaguchi K/2004 [24] Japan Osteoarthritis secondary to hip dysplasia Uncemented Etidronate (G1) No medication 5 2 26 22 1 year No medication 30 months 30 months 2 0
Iwamoto N/2011 [25] Japan Osteoarthritis Uncemented Alendronate (G3) No medication 4 5 16 17 48 weeks no medication 48 weeks 48 weeks 2 0
Kinov P/2006 [26] Bulgaria Osteoarthritis, osteonecrosis, or hip fracture Cemented or hybrid Risedronate (G3) Placebo 4 5 8 7 0.5 year 0.5 year 0.5 year 0.5 year 0 0
Shetty N/2006 [27] England Primary or secondary osteoarthritis Hybrid Pamidronate (G2) Placebo 12 10 6 9 50 days 50 days 5 years 5 years 1 1
Scott DF/2013 [28] America NA Uncemented Zoledronate (G3) Placebo + calcium 12 11 15 13 Twice administration Twice administration 2 years 2 years 0 0
Yukizawa Y/2017 [29] Japan Osteoarthritis Uncemented Alendronate (G3) No medication 4 7 14 9 ≥ 2 years no medication ≥ 9 years ≥ 9 years 0 0
Muren O/2015 [30] Sweden Osteoarthritis Uncemented Risedronate (G3) Placebo + calcium 20 18 10 13 0.5 year 0.5 year 4 years 4 years 0 0
Nehme A/2003 [31] Lebanon Degenerative hip disease Cemented Alendronate (G3) Placebo + calcium NA NA NA NA 2 years 2 years 2 years 2 years 0 0
  1. THA total hip arthroplasty, BPs bisphosphonates, NA not applicable